aTyr Pharma to Participate in Piper Sandler Investor Lung Day

On October 11, 2021 aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, reported that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler Virtual Investor Day: Developing Therapeutics for Lung Indications on Friday, October 15, 2021, at 9:00am ET / 6:00am PT (Press release, aTyr Pharma, OCT 11, 2021, View Source [SID1234591074]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The discussion will be moderated by Ted Tenthoff, Senior Research Analyst at Piper Sandler.

Following the event, a replay of the fireside chat will be available on the Investor’s section of the company’s website at www.atyrpharma.com and will be available for at least 90 days.

Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness

On October 11, 2021 Allergan Aesthetics, an AbbVie company (NYSE: ABBV), reported that it is continuing its commitment to breast health, awareness, restoration, and research in support of breast cancer awareness month (Press release, AbbVie, OCT 11, 2021, View Source [SID1234591058]). For the month of October and into 2022, Allergan Aesthetics , The Power of You campaign will kick off a new series of initiatives and partnerships to support organizations creating a measurable impact in the fight against breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Power of You supports women as they navigate breast cancer. The campaign showcases real women and their authentic stories of courage, strength, and community as they embark on their journeys ahead. "Allergan Aesthetics is about empowering confidence in people every day. Through our Breast Cancer Awareness work, we are dedicated to educating women on their choices, and supporting women for what’s ahead," says Carrie Strom, Senior Vice President, AbbVie, and President, Global Allergan Aesthetics.

Starting October, Breast Cancer Awareness Month, and into 2022, Allergan Aesthetics will launch the following initiatives:

GOLDSHEEP: Limited Edition Breast Cancer Awareness Capsule Collection (October) – In partnership with Allergan Aesthetics and Keep A Breast, the athleisure brand, will launch their coveted #ISweatPink capsule collection including co-branded designs. 100% of the net proceeds from the limited-edition collection will be donated to Keep A Breast, an organization dedicated to educating women on Breast Cancer prevention and early detection. To contribute to the cause, Allergan Aesthetics will make an additional sponsorship of $10,000. Link to purchase HERE.
VIRTUAL FUNDRAISER: Bust A Move (October 16th) – Allergan Aesthetics will be partnering with Bust A Move for a series of live classes on the Peloton app that consumers can join throughout the day. The organization’s mission is to increase awareness of the differences in breast cancer in African American, Latina and younger populations. 100% of the money raised will go to four (4) different breast cancer organizations with an additional $50,000 by Allergan Aesthetics. Share, tag and challenge friends on social using #BUSTAMOVE. Link to sign up HERE.
PROJECT RESTORED: Book Launch (November 15th & 16) – Restored, a book by Erez Sabag and David Warren in collaboration with Jonathan Bank, MD and Ron Israeli, MD, illustrates the power of breast reconstruction by following twelve women’s journeys. Sponsored by Allergan Aesthetics, 100% of the profits from the sale of the book will go to the AiRs Foundation. The project will host a two-day exhibit in New York City featuring photographs, video, and the women’s life cast sculptures to launch the book. To learn more please visit, restoredexhibit.com
LADY: The Film (Fall 2022) – Supported by Allergan Aesthetics, the film is based on actress Devin Sidell’s personal story about testing positive for the BRCA1 mutation and her preventative surgeries and breast reconstruction. A dramedy-fantasy, it addresses complicated medical decisions, family relationships, and ultimately, the choice to put yourself first. Link for more information HERE.
Allergan Aesthetics’ year-round mission to support Breast Cancer Awareness also includes the Sisters Network BCAP Program & Stop the Silence Walk, Pink Lemonade Project MBC Educational Webinar (April 2021), LBBC Reach and Raise (May 2021), BCRC Art Bra Austin Virtual Runway Show (June 2021) and continued partnership in the Komen More Than Pink Walks in Orange County, Austin, San Francisco, New Jersey and Chicago.

Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021

On October 11, 2021 Horizon Therapeutics plc (Nasdaq: HZNP) reported that its third-quarter 2021 financial results will be released on Wednesday, Nov. 3, 2021 (Press release, Horizon Therapeutics, OCT 11, 2021, View Source [SID1234591075]). Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast and a replay may be accessed at View Source Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress

On October 11, 2021 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that it will present early clinical data for repotrectinib from the ongoing Phase 1/2 CARE study in pediatric and young adult patients with advanced solid tumors harboring ALK, ROS1 or NTRK alterations at the virtual 53rd Congress of the International Society of Paediatric Oncology (SIOP) being held October 21-24 (Press release, Turning Point Therapeutics, OCT 11, 2021, View Source [SID1234591109]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the Presentation
Presentation Title: A Phase 1/2, open-label study of repotrectinib in pediatric and young adult patients with advanced or metastatic malignancies harboring ALK, ROS1, or NTRK1-3 alterations
Session Name: 910 – FPS 04-Live Q&A-New Drugs/Experimental Therapeutics
Session Type: Free Paper Session (FPS)
Date / Session Time: Saturday, October 23, 2021, 8:40 – 9:40 a.m. ET
Lecture Time: 9:12 – 9:22 a.m. ET
Presenter: Steven G. Dubois, M.D., Associate Professor of Pediatrics, Harvard Medical School, Director, Experimental Therapeutics for Pediatric Oncology, Dana-Farber Cancer Institute

The presentation from SIOP 2021 will be available on the company’s website shortly after the event at www.tptherapeutics.com.

Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International

On October 11, 2021 Ipsen (Euronext: IPN; ADR: IPSEY) reported the appointment of Mari Scheiffele as EVP and President, Specialty Care International, effective November 1st 2021 (Press release, Ipsen, OCT 11, 2021, View Source [SID1234591038]). Based in Boulogne, France, she will be reporting directly to David Loew, CEO, Ipsen, and serve on the Executive Leadership Team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Along with the ELT, we are very pleased to welcome Mari to Ipsen. Her diverse experience will be critical in developing our three key therapeutic areas, Oncology, Rare Disease and Neuroscience, by continuing to strengthen Ipsen’s international commercial presence in over 115 countries, excluding North America. Mari also brings valuable capabilities in transformation which she built over the course of her previous roles at Novartis and McKinsey. We are looking forward to working closely with her," said David Loew, CEO, Ipsen.

Mari brings 20 years of healthcare leadership experience, from across the industry, having worked in the US, Europe and in Japan. She joins Ipsen from Novartis where she has been in both global strategic and country operational roles, first in Japan and then in the UK. Most recently, Mari has been General Manager, Novartis Oncology UK & Ireland where with a focus on patient-centricity, evidence-based medicine, and partnership, she has driven a successful business transformation.

In addition to her depth in Oncology, Mari has worked in other specialty care environments such as ophthalmology, neuroscience and immunology. Prior to Novartis, Mari was a partner at McKinsey & Company in New York and in Switzerland in Pharmaceuticals and Medical Products.

"I’m delighted to be joining Ipsen at such an exciting time," said Mari Scheiffele. "Ipsen has an inspiring strategy, strong growth and a fantastic culture of collaboration, and excellence. I look forward to working with my new colleagues on Ipsen’s International team, across its broad reach of markets, to bring Ipsen’s transformative innovations to patients around the World."

Mari speaks English, Finnish and Japanese and holds a doctorate in neuroscience from Harvard Medical School.